Exact Mass: 439.142

Exact Mass Matches: 439.142

Found 36 metabolites which its exact mass value is equals to given mass value 439.142, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Sporamin

(1S,2R,4S,5S)-9-butyl-7-[(3-hydroxy-2-phenylpropanoyl)oxy]-9-methyl-3-oxa-9-azatricyclo[3.3.1.0²,⁴]nonan-9-ium bromide

C21H30BrNO4 (439.1358)


The major storage protein of sweet potato tubers Ipomoea batatas accounting for ca. 80\\% of total soluble protein. Possesses Trypsin inhibiting activity which may have a defense role against tuber damage. Sporamin is found in root vegetables.

   

Scopolamine butylbromide

(-)scopolamine N-butyl bromide

C21H30BrNO4 (439.1358)


   

Hyoscine_butylbromide

3-OXA-9-AZONIATRICYCLO(3.3.1.0 SUP(2,4))NONANE, 9-BUTYL-7-((2S)-3-HYDROXY-1-OXO-2-PHENYLPROPOXY)-9-METHYL-, BROMIDE (1:1),(1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,7.BETA.)-

C21H30NO4+.Br- (439.1358)


Butylscopolamine bromide is an organic bromide salt of butylscopolamine. It is an antispasmodic drug which can relieve painful stomach cramps (including those linked with irritable bowel syndrome), bladder and menstrual cramps. It has a role as a muscarinic antagonist and an antispasmodic drug. It is an organic bromide salt and a quaternary ammonium salt. It contains a butylscopolamine. Butylscopolamine Bromide is an orally available bromide salt form of butylscopolamine, a quaternary ammonium derivative of the alkaloid scopolamine, with anticholinergic property. Upon oral administration, hyoscine butylbromide binds to and blocks muscarinic receptors located on postganglionic parasympathetic nerve endings and on smooth muscle cells. This blocks the activity of acetylcholine (Ach) and causes its antispasmodic effect in the gastrointestinal (GI), urinary, uterine, and biliary tracts. This agent may also facilitate radiologic visualization of the GI tract. Antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal, urinary, uterine, and biliary tracts, and to facilitate radiologic visualization of the gastrointestinal tract. C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent

   
   

S-p-Coumarylglutathione

S-p-Coumarylglutathione

C19H25N3O7S (439.1413)


   

Nitrile,O-beta-D-glucopyranoside-,tetra-Ac-1-Hydroxy-2-cyclopentene-1-carboxylic acid

Nitrile,O-beta-D-glucopyranoside-,tetra-Ac-1-Hydroxy-2-cyclopentene-1-carboxylic acid

C20H25NO10 (439.1478)


   

(S)-2-amino-5-((R)-1-(carboxymethylamino)-3-((E)-3-(4-hydroxyphenyl)allylthio)-1-oxopropan-2-ylamino)-5-oxopentanoic acid|S-p-hydroxycinnamylglutathione

(S)-2-amino-5-((R)-1-(carboxymethylamino)-3-((E)-3-(4-hydroxyphenyl)allylthio)-1-oxopropan-2-ylamino)-5-oxopentanoic acid|S-p-hydroxycinnamylglutathione

C19H25N3O7S (439.1413)


   

1-O-acetyldauricumine

1-O-acetyldauricumine

C21H26ClNO7 (439.1398)


   

4-Aminophenyl 2,3,4,6-tetra-O-acetyl-a-D-mannopyranoside

4-Aminophenyl 2,3,4,6-tetra-O-acetyl-a-D-mannopyranoside

C20H25NO10 (439.1478)


   

Hyoscine_butylbromide

3-OXA-9-AZONIATRICYCLO(3.3.1.0 SUP(2,4))NONANE, 9-BUTYL-7-((2S)-3-HYDROXY-1-OXO-2-PHENYLPROPOXY)-9-METHYL-, BROMIDE (1:1),(1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,7.BETA.)-

C21H30BrNO4 (439.1358)


Butylscopolamine bromide is an organic bromide salt of butylscopolamine. It is an antispasmodic drug which can relieve painful stomach cramps (including those linked with irritable bowel syndrome), bladder and menstrual cramps. It has a role as a muscarinic antagonist and an antispasmodic drug. It is an organic bromide salt and a quaternary ammonium salt. It contains a butylscopolamine. Butylscopolamine Bromide is an orally available bromide salt form of butylscopolamine, a quaternary ammonium derivative of the alkaloid scopolamine, with anticholinergic property. Upon oral administration, hyoscine butylbromide binds to and blocks muscarinic receptors located on postganglionic parasympathetic nerve endings and on smooth muscle cells. This blocks the activity of acetylcholine (Ach) and causes its antispasmodic effect in the gastrointestinal (GI), urinary, uterine, and biliary tracts. This agent may also facilitate radiologic visualization of the GI tract. Antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal, urinary, uterine, and biliary tracts, and to facilitate radiologic visualization of the gastrointestinal tract. C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent

   

2-[[4-[(2-cyano-3-nitrophenyl)azo]-m-tolyl](2-acetoxyethyl)amino]ethyl acetate

2-[[4-[(2-cyano-3-nitrophenyl)azo]-m-tolyl](2-acetoxyethyl)amino]ethyl acetate

C21H21N5O6 (439.1492)


   

Pyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-trione,7-[2-(acetyloxy)ethyl]-6-hydroxy-1,3-dimethyl-9-(phenylmethyl)-

Pyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-trione,7-[2-(acetyloxy)ethyl]-6-hydroxy-1,3-dimethyl-9-(phenylmethyl)-

C21H21N5O6 (439.1492)


   

(S)-(-)-1-(2-Diphenylphosphino-1-naphthyl)isoquinoline (S)-QUINAP

(S)-(-)-1-(2-Diphenylphosphino-1-naphthyl)isoquinoline (S)-QUINAP

C31H22NP (439.149)


   

N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]-3,4,5-trimethoxybenzamide

N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]-3,4,5-trimethoxybenzamide

C19H22FN3O8 (439.1391)


   

(S)-2-(Z-AMINO)-3-PHENYLPROPYL TOLUENE-4-SULFONATE

(S)-2-(Z-AMINO)-3-PHENYLPROPYL TOLUENE-4-SULFONATE

C24H25NO5S (439.1453)


   

Tie2 kinase inhibitor

4-(4-(6-methoxynaphthalen-2-yl)-2-(4-(methylsulfinyl)phenyl)-1H-imidazol-5-yl)pyridine

C26H21N3O2S (439.1354)


   

S-1,2,3,4-TETRAHYDRO-3-ISOQUINOLINE CARBOXYLIC ACID BENZYL ESTER P-TOLUENESULFONIC ACID SALT

S-1,2,3,4-TETRAHYDRO-3-ISOQUINOLINE CARBOXYLIC ACID BENZYL ESTER P-TOLUENESULFONIC ACID SALT

C24H25NO5S (439.1453)


   

2-[N-(2-acetyloxyethyl)-4-[(2-cyano-4-nitrophenyl)diazenyl]anilino]ethyl acetate

2-[N-(2-acetyloxyethyl)-4-[(2-cyano-4-nitrophenyl)diazenyl]anilino]ethyl acetate

C21H21N5O6 (439.1492)


   

(r)-(+)-1-(2-diphenylphosphino-1-naphthyl)isoquinoline

(r)-(+)-1-(2-diphenylphosphino-1-naphthyl)isoquinoline

C31H22NP (439.149)


   

BIA-3-335 free base

BIA-3-335 free base

C20H20F3N3O5 (439.1355)


   

Dimethyl 5-{3-[2-(4-methylbenzoyl)hydrazino]-2,5-dioxo-1-pyrrolidinyl}isophthalate

Dimethyl 5-{3-[2-(4-methylbenzoyl)hydrazino]-2,5-dioxo-1-pyrrolidinyl}isophthalate

C22H21N3O7 (439.1379)


   

1-[(4-Fluorophenyl)methyl]-3-(2-furanylmethyl)-4-imino-6,6-dimethyl-5,8-dihydropyrano[2,3]thieno[2,4-b]pyrimidin-2-one

1-[(4-Fluorophenyl)methyl]-3-(2-furanylmethyl)-4-imino-6,6-dimethyl-5,8-dihydropyrano[2,3]thieno[2,4-b]pyrimidin-2-one

C23H22FN3O3S (439.1366)


   

4-(5-methyl-3-nitro-1-pyrazolyl)-N-[3-(4-methylphenoxy)-5-nitrophenyl]butanamide

4-(5-methyl-3-nitro-1-pyrazolyl)-N-[3-(4-methylphenoxy)-5-nitrophenyl]butanamide

C21H21N5O6 (439.1492)


   

(2R,3R,3aS,9bS)-1-[(3-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-N-(2,2,2-trifluoroethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

(2R,3R,3aS,9bS)-1-[(3-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-N-(2,2,2-trifluoroethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

C21H21F4N3O3 (439.1519)


   

(2R,3R,3aS,9bS)-7-(2-fluorophenyl)-3-(hydroxymethyl)-1-methyl-6-oxo-N-(2,2,2-trifluoroethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

(2R,3R,3aS,9bS)-7-(2-fluorophenyl)-3-(hydroxymethyl)-1-methyl-6-oxo-N-(2,2,2-trifluoroethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

C21H21F4N3O3 (439.1519)


   

(2S,3S,3aR,9bR)-1-[(3-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-N-(2,2,2-trifluoroethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

(2S,3S,3aR,9bR)-1-[(3-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-N-(2,2,2-trifluoroethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

C21H21F4N3O3 (439.1519)


   

(2S,3S,3aR,9bR)-7-(2-fluorophenyl)-3-(hydroxymethyl)-1-methyl-6-oxo-N-(2,2,2-trifluoroethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

(2S,3S,3aR,9bR)-7-(2-fluorophenyl)-3-(hydroxymethyl)-1-methyl-6-oxo-N-(2,2,2-trifluoroethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide

C21H21F4N3O3 (439.1519)


   

2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(3-oxo-1-phenylpropyl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid

2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(3-oxo-1-phenylpropyl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid

C19H25N3O7S (439.1413)


   

Zamaporvint

Zamaporvint

C21H16F3N7O (439.1368)


Zamaporvint (RXC004) is an orally active and selective inhibitor of Wnt. Zamaporvint targete membrane-bound o-acyltransferase Porcupine and inhibited Wnt ligand palmitoylation, secretion, and pathway activation. Zamaporvint displays a favorable pharmacokinetic profile and shows potent antiproliferative effects in Wnt ligand-dependent colorectal and pancreatic cell lines. Zamaporvint possesses multiple antitumor mechanisms and can be used in cancer research[1].

   

3-{3-[2-(hydroxymethyl)-3-methoxyphenyl]-10-methyl-5-oxo-2-azatricyclo[6.3.1.0⁴,¹²]dodeca-1(11),3,6,8(12),9-pentaen-2-yl}benzoic acid

3-{3-[2-(hydroxymethyl)-3-methoxyphenyl]-10-methyl-5-oxo-2-azatricyclo[6.3.1.0⁴,¹²]dodeca-1(11),3,6,8(12),9-pentaen-2-yl}benzoic acid

C27H21NO5 (439.142)


   

methyl (1r,3r,4r,5r,7r,9r,11s,12s,13s)-5-(6-aminopurin-9-yl)-1,4,12,13-tetrahydroxy-2,6,10-trioxatricyclo[7.4.0.0³,⁷]tridecane-11-carboxylate

methyl (1r,3r,4r,5r,7r,9r,11s,12s,13s)-5-(6-aminopurin-9-yl)-1,4,12,13-tetrahydroxy-2,6,10-trioxatricyclo[7.4.0.0³,⁷]tridecane-11-carboxylate

C17H21N5O9 (439.1339)


   
   

(2s)-2-amino-4-{[(1r)-1-(carboxymethyl-c-hydroxycarbonimidoyl)-2-{[(2e)-3-(4-hydroxyphenyl)prop-2-en-1-yl]sulfanyl}ethyl]-c-hydroxycarbonimidoyl}butanoic acid

(2s)-2-amino-4-{[(1r)-1-(carboxymethyl-c-hydroxycarbonimidoyl)-2-{[(2e)-3-(4-hydroxyphenyl)prop-2-en-1-yl]sulfanyl}ethyl]-c-hydroxycarbonimidoyl}butanoic acid

C19H25N3O7S (439.1413)


   

4-{3-[2-(hydroxymethyl)-3-methoxyphenyl]-10-methyl-5-oxo-2-azatricyclo[6.3.1.0⁴,¹²]dodeca-1(11),3,6,8(12),9-pentaen-2-yl}benzoic acid

4-{3-[2-(hydroxymethyl)-3-methoxyphenyl]-10-methyl-5-oxo-2-azatricyclo[6.3.1.0⁴,¹²]dodeca-1(11),3,6,8(12),9-pentaen-2-yl}benzoic acid

C27H21NO5 (439.142)


   

(2s)-2-amino-4-{[(1r)-1-(carboxymethyl-c-hydroxycarbonimidoyl)-2-{[3-(4-hydroxyphenyl)prop-2-en-1-yl]sulfanyl}ethyl]-c-hydroxycarbonimidoyl}butanoic acid

(2s)-2-amino-4-{[(1r)-1-(carboxymethyl-c-hydroxycarbonimidoyl)-2-{[3-(4-hydroxyphenyl)prop-2-en-1-yl]sulfanyl}ethyl]-c-hydroxycarbonimidoyl}butanoic acid

C19H25N3O7S (439.1413)


   

methyl (1r,3s,4s,5r,7r,9r,11s,12s,13s)-5-(6-aminopurin-9-yl)-1,4,12,13-tetrahydroxy-2,6,10-trioxatricyclo[7.4.0.0³,⁷]tridecane-11-carboxylate

methyl (1r,3s,4s,5r,7r,9r,11s,12s,13s)-5-(6-aminopurin-9-yl)-1,4,12,13-tetrahydroxy-2,6,10-trioxatricyclo[7.4.0.0³,⁷]tridecane-11-carboxylate

C17H21N5O9 (439.1339)